NCT07178353 Human Skeletal Muscle Response to 5 Days of Bedrest in Young Adults
| NCT ID | NCT07178353 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen's University |
| Condition | Muscular Atrophy |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2025-09 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2025-09 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this intervention trial is to characterize skeletal muscle atrophy in healthy, young adults during short term bedrest. The main questions it aims to answer are: How much do skeletal muscle volume, strength, and fatigue resistance decline during bedrest? How much does whole-body insulin sensitivity change during bedrest? How do mitochondrial function and protein synthesis change during bedrest? Participants will undergo the following tests before and after a free-living control period and before and after a 5 day period of strict horizontal bedrest: * Magnetic resonance imaging of the thigh muscles * Strength testing of the thigh muscles * Insulin sensitivity testing in response to a mixed meal * Exogenous glucose oxidation in response to a mixed meal * Muscle biopsies from the thigh muscles * Blood samples
Eligibility Criteria
Inclusion Criteria: * Males and females 18-30 years * BMI between 18.5-28 kg/m2 * Weight stable (within ±2kg for 6 months) * Generally healthy as assessed by medical and physical activity questionnaires * recreationally active Exclusion Criteria: * a BMI \< 18.5 and \> 28 kg/m2 * the use of insulin to control blood glucose levels * a history of any cardiovascular, respiratory, metabolic diseases, neuromuscular or bone-wasting diseases * the use of any medication that may affect muscle protein turnover (e.g. androgen or anabolic hormone therapy, chemotherapy) * a (family) history of thrombosis, platelet or coagulation disorders, or antiplatelet therapy and the use of anticoagulant medications * the presence of any unremoved, or partially removed metals underneath the skin * a history of head or eye injury involving metal fragments * have some type of implanted electrical device (such as a cardiac pacemaker or neurostimulator) * have implanted metal objects as a result of surgery, such as artificial joints, aneurysm clips, metal staples * are, or may be, pregnant * are wearing metal braces on their teeth.
Contact & Investigator
Chris McGlory, PhD.
PRINCIPAL INVESTIGATOR
Queen's University
Frequently Asked Questions
Who can join the NCT07178353 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Muscular Atrophy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07178353 currently recruiting?
Yes, NCT07178353 is actively recruiting participants. Contact the research team at chris.mcglory@queensu.ca for enrollment information.
Where is the NCT07178353 trial being conducted?
This trial is being conducted at Kingston, Canada.
Who is sponsoring the NCT07178353 clinical trial?
NCT07178353 is sponsored by Queen's University. The principal investigator is Chris McGlory, PhD. at Queen's University. The trial plans to enroll 12 participants.